The study will enrol Chinese subjects with ocular inflammation and pain following ophthalmic surgery. Credit: Paul Diaconu from Pixabay.

China’s National Medical Products Administration (NMPA) has approved the clinical trial application (CTA) of AffaMed Therapeutics to initiate a Phase III registrational study in the country to evaluate DEXTENZA in subjects following ophthalmic surgery.

DEXTENZA is being developed to become a sustained-release intracanalicular insert for delivering a preservative-free dexamethasone dose for up to 30 days with one administration.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Designed to assess the efficacy and safety of DEXTENZA, the study will enrol Chinese subjects with ocular inflammation and pain following ophthalmic surgery.

AffaMed and Ocular Therapeutix signed a licensing deal in October 2020 to develop and market DEXTENZA in Greater China, South Korea, and some ASEAN markets.

In addition to treatment of ocular inflammation and pain following ophthalmic surgery, DEXTENZA is approved in the US and Macau for ocular itching associated with allergic conjunctivitis.

AffaMed CEO Dr Dayao Zhao said: “We are encouraged by the Chinese regulator’s efficiency in approving our application for this novel therapy, based on the proposed Phase III study design and the totality of the existing registrational trial data previously submitted by our partner Ocular Therapeutix to the US FDA.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are ready to start the Phase III trial, and we are looking forward to completing the development of DEXTENZA so that we can bring this novel and differentiated treatment option to patients in China as soon as possible.”

AffaMed is planning to announce the top-line data from the Phase III study in the fourth quarter of this year.